---
title: Incretin Effect in Patients With Psoriasis and Controls
nct_id: NCT06064084
overall_status: COMPLETED
sponsor: University Hospital, Gentofte, Copenhagen
study_type: OBSERVATIONAL
primary_condition: Psoriasis Vulgaris
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06064084.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06064084"
ct_last_update_post_date: 2023-10-03
last_seen_at: "2026-05-12T06:41:16.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Incretin Effect in Patients With Psoriasis and Controls

**Official Title:** Incretin Effect in Patients With Psoriasis

**NCT ID:** [NCT06064084](https://clinicaltrials.gov/study/NCT06064084)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 24
- **Lead Sponsor:** University Hospital, Gentofte, Copenhagen
- **Conditions:** Psoriasis Vulgaris
- **Start Date:** 2011-09-11
- **Completion Date:** 2015-09-11
- **CT.gov Last Update:** 2023-10-03

## Brief Summary

To investigate the incretin effect and postprandial incretin responses in plasma in patients with psoriasis

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

```
Inclusion Criteria:

no diabetes BMI \< 27 kg/m\^2 normal Glucose tolerance test at screening normal fasting plasma glucose no islet auto antibodies no hormonel contraception informed consent psoriasis vulgaris (PASI\>8) (case not controls)

Exclusion Criteria:

other chronic inflammtory skin disease other chronic inflammatory disease pregnancy psychiatric illness
```

## Arms

- **Psoriasis**
- **Control** — Age, Sex and BMI matched

## Interventions

- **Oral glucose tolerance test** (DIAGNOSTIC_TEST) — Oral glucose tolerance test 50g
- **Intravenous isoglycaemic glucose clamp** (OTHER) — Intravenous isoglycaemic glucose clamp
- **Liquid Mixed meal test** (OTHER) — Liquid Mixed meal test 520 kcal

## Primary Outcomes

- **Incretin effect measured with Beta-cell secretory response** _(time frame: 0-180 minutes)_ — Incretineffect (%) = 100 % × (Beta-cell Secretory Response (OGTT) - Beta-cell Secretory Response (IIGI)) / Beta-cell Secretory Response (OGTT)

## Secondary Outcomes

- **Insulin sensitivity measures** _(time frame: 0-180 minutes)_
- **Concentration of Glucose-independent insulinotropic polypeptide** _(time frame: 0-180 minutes)_
- **Concentration of Glucagon-like peptide 1** _(time frame: 0-180 minuntes)_
- **Concentration of Glucagon** _(time frame: 0-180 minutes)_
- **Concentration of Insulin** _(time frame: 0-180 minutes)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06064084.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06064084*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*